<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Jin H</submitter><funding>Natural Science Foundation of China</funding><funding>Wenzhou Science and Technology Bureau</funding><funding>Wenzhou Medical University</funding><funding>Startup Foundation for Hundred-Talent Program of Zhejiang University</funding><funding>Key Discipline of Zhejiang Province in Medical Technology</funding><funding>Key Project of Science and Technology Innovation Team of Zhejiang Province</funding><funding>National Natural Science Foundation of China</funding><pagination>840-854</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8078721</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>17(4)</volume><pubmed_abstract>Although &lt;i>MIR516A&lt;/i> has been reported to be downregulated and act as a tumor suppressor in multiple cancers, its expression and potential contribution to human bladder cancer (BC) remain unexplored. Unexpectedly, we showed here that &lt;i>MIR516A&lt;/i> was markedly upregulated in human BC tissues and cell lines, while inhibition of &lt;i>MIR516A&lt;/i> expression attenuated BC cell monolayer growth &lt;i>in vitro&lt;/i> and xenograft tumor growth &lt;i>in vivo&lt;/i>, accompanied with increased expression of PHLPP2. Further studies showed that &lt;i>MIR516A&lt;/i> was able to directly bind to the 3'-untranslated region of &lt;i>PHLPP2&lt;/i> mRNA, which was essential for its attenuating PHLPP2 expression. The knockdown of &lt;i>PHLPP2&lt;/i> expression in &lt;i>MIR516A&lt;/i>-inhibited cells could reverse BC cell growth, suggesting</pubmed_abstract><journal>Autophagy</journal><pubmed_title>Oncogenic role of &lt;i>MIR516A&lt;/i> in human bladder cancer was mediated by its attenuating PHLPP2 expression and BECN1-dependent autophagy.</pubmed_title><pmcid>PMC8078721</pmcid><funding_grant_id>First Class</funding_grant_id><funding_grant_id>Category A</funding_grant_id><funding_grant_id>2013TD10</funding_grant_id><funding_grant_id>Y20170028</funding_grant_id><funding_grant_id>2017R413064</funding_grant_id><funding_grant_id>Y20190065</funding_grant_id><funding_grant_id>NSFC81702530</funding_grant_id><funding_grant_id>NSFC81872587</funding_grant_id><funding_grant_id>89216021</funding_grant_id><pubmed_authors>Li H</pubmed_authors><pubmed_authors>Huang C</pubmed_authors><pubmed_authors>Liu L</pubmed_authors><pubmed_authors>Lu Y</pubmed_authors><pubmed_authors>Huang H</pubmed_authors><pubmed_authors>Chen C</pubmed_authors><pubmed_authors>Xie Q</pubmed_authors><pubmed_authors>Chang Y</pubmed_authors><pubmed_authors>Xu J</pubmed_authors><pubmed_authors>Zang N</pubmed_authors><pubmed_authors>Tian Z</pubmed_authors><pubmed_authors>Zhao N</pubmed_authors><pubmed_authors>Jin H</pubmed_authors><pubmed_authors>Fang Z</pubmed_authors><pubmed_authors>Huang X</pubmed_authors><pubmed_authors>Ma J</pubmed_authors><pubmed_authors>Wang X</pubmed_authors></additional><is_claimable>false</is_claimable><name>Oncogenic role of &lt;i>MIR516A&lt;/i> in human bladder cancer was mediated by its attenuating PHLPP2 expression and BECN1-dependent autophagy.</name><description>Although &lt;i>MIR516A&lt;/i> has been reported to be downregulated and act as a tumor suppressor in multiple cancers, its expression and potential contribution to human bladder cancer (BC) remain unexplored. Unexpectedly, we showed here that &lt;i>MIR516A&lt;/i> was markedly upregulated in human BC tissues and cell lines, while inhibition of &lt;i>MIR516A&lt;/i> expression attenuated BC cell monolayer growth &lt;i>in vitro&lt;/i> and xenograft tumor growth &lt;i>in vivo&lt;/i>, accompanied with increased expression of PHLPP2. Further studies showed that &lt;i>MIR516A&lt;/i> was able to directly bind to the 3'-untranslated region of &lt;i>PHLPP2&lt;/i> mRNA, which was essential for its attenuating PHLPP2 expression. The knockdown of &lt;i>PHLPP2&lt;/i> expression in &lt;i>MIR516A&lt;/i>-inhibited cells could reverse BC cell growth, suggesting</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Apr</publication><modification>2026-07-09T11:33:30.116Z</modification><creation>2026-07-09T10:50:51.077Z</creation></dates><accession>S-EPMC8078721</accession><cross_references><pubmed>32116109</pubmed><doi>10.1080/15548627.2020.1733262</doi></cross_references></HashMap>